NWBO News and Press, Northwest Biotherapeutics Inc. From 12/18/20

Robinhood Penny Stocks To Watch Next Week In December 2020, there are plenty of options when it comes to penny stocks to watch . While these cheap stocks are quite volatile, there are ways that traders can use this volatility to their advantage. One of the best ways to start finding...

Data lock has been announced, and top line data is to be expected within a few weeks. Trial duration hints towards longer survival than Standard of Care. No other drug can explain this long survival. Cel-Sci might have a potential blockbuster drug in the making. For furt...

Data is Locked. NWBO's Data Lock announcement boosted their Market Cap to nearly $2B. Full Data announcement is imminent. CEL-SCI appears to be preparing a BLA. Positive data will bring a share price between $80 - $200. For further details see: CEL-SCI: Data Lock...

Should These Be On Your List Of Penny Stocks To Buy Today? Penny stocks have become synonymous with both institutional and retail investors in the past six months. There are a few reasons why penny stocks are seeing so much popularity in that time frame. For one, penny stocks are de...

Why Are These Penny Stocks Seeing Newfound Attention? Penny stocks have continued to bring in newfound attention in the stock market. The term penny stock itself simply means any stock that is trading under $5. As you can see, this opens up quite a long list of possibilities. And wi...

Are These Biotech Penny Stocks On Your Watch List Right Now? While the traders digest the latest news in the stock market today, penny stocks remain a focal point. These cheap stocks are some of the most exciting especially during times where volatility might be lacking in the broad...

When it comes to winning biotech stocks this year, coronavirus vaccine developers automatically come to many investors' minds. However, one of the top-performing stocks in the sector is Northwest Biotherapeutics (OTC: NWBO) , which focuses on immunotherapies that treat can...

Palm Beach, FL – October 21, 2020 – Cancer immunotherapy has emerged as a new avenue for revenue generation for pharmaceutical companies. Adverse effects, such as recurrence of cancer and organ failure, associated with conventional chemotherapies and rising demand for technolo...

With Data Lock just announced, Top Line Date is imminent. Numerous statistical and mathematical markers from available data shine a positive light on potential trial results. The company may have a lucrative option even if median Overall Survival does not meet the second...

Northwest Biotherapeutics ([[NWBO]] +2.6%) announced that the database for the Phase III trial of DCVax-L for Gliobastoma has been locked.Pipeline:Independent service firms managing the clinical trial will now arrange for the independent statisticians to have access to the unblinded raw ...